Stock 1801 INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Delayed Hong Kong S.E.
Other stock markets
 07:07:30 30/04/2024 BST 		5-day change 1st Jan Change
38.25 HKD -3.77% Intraday chart for Innovent Biologics, Inc. +5.81% -10.53%
06:30am Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer CI
04-17 Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
AQ
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
AQ
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
AQ
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
AQ
Innovent Releases Final Analysis Results of ORIENT-15, the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
AQ
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT in Two New Indications Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
AQ
Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
AQ
China NMPA Approves TYVYT (sintilimab) In Combination With Chemotherapy For Gastric Cancer
AQ
OPKO Health : to Develop and Commercialize RAYALDEE in Greater China with Nicoya Therapeutics
AQ
Innovent Biologics : Form of Proxy for use at the Annual General Meeting to be held on Thursday, June 24, 2021
PU
Innovent Biologics : PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
PU
Innovent Biologics : INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON SALES OF TYVYT (SINTILIMAB INJECTION) IN THE FIRST QUARTER OF 2021
PU
Innovent Biologics : GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES
PU
Innovent Biologics : Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress
PR
Innovent Biologics : Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
PR
Innovent Biologics : and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
PR
Innovent Biologics : Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia
PR
Innovent Biologics : Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)
PR
Innovent Biologics : Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
PR
Innovent Biologics : Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. News Innovent Biologics, Inc.
  5. Press Releases